P/E của cổ phiếu EXEL là bao nhiêu?

Exelixis Inc (EXEL) hiện giao dịch ở mức P/E 15.99 lần.

ROE của cổ phiếu EXEL là bao nhiêu?

Exelixis Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 43.05%.

Tỷ suất cổ tức của EXEL là bao nhiêu?

Exelixis Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của EXEL là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của EXEL ở mức 100/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu EXEL không?

Điểm AI Timing của EXEL là 69/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu EXEL thuộc ngành nào?

Exelixis Inc được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu EXEL (NASDAQ) | EXELIXIS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

EXEL AI Analysis Summary

Our AI summary for EXEL: Exelixis Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 15.99, ROE of 43.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

EXEL

Exelixis Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 97

USD 55.06

2.03 (3.83%) Day Change

Watchlist Portfolio Compare Chart

15.99

P/E

0.34

D/E

43.1%

ROE

32.1%

ROA

0.00%

Div Yield

0.20

PEG

EXELIXIS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 55.06 Price 2.03 (3.83%) Day Change	NEWS SCORE: 97

EXEL Chất lượng tổng thể của cố phiếu Xuất sắc ( Chất lượng = 100) và Thời điểm mua ...(Sign In to See)...

Loading chart...

100 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Excellent

Reason: Sức khỏe tài chính của công ty Xuất sắc từ hầu hết các chỉ số chất lượng

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Khá , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

64%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.82 From 30 days period
News Score	97
Magic Formula Rank by ROA	398
Magic Formula Rank by ROE	398
Magic Formula Rank by ROIC	440
Price	55.06
PBV / Sector	6.89 / 44,219.29
Earning Per Share	3.44

PE / Sector	15.99 / 19.28
PEG or PE/Growth / Sector	0.20 / 1.23 GREAT
Average 1M Daily Value	126.23 M GREAT
Average 1W Daily Value	151.45 M GREAT

Yếu tố Kỹ thuật

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

77%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	35.08 / 98.22 GREAT
NPM Average (%) / Sector	23.10 / -1,697.63 GREAT
NPM Change Average (%) / Sector	39.10 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	32.13 / 185,260.96 GREAT
ROA Average (%) / Sector	18.07 / 36,684.70 GOOD
ROA Change Average (%) / Sector	60.45 / 422,221.66 GREAT
ROE (%) / Sector	43.05 / 243,762.23 GREAT
ROE Average (%) / Sector	23.80 / 48,758.47 GOOD
ROE Change Average (%) / Sector	63.29 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Chi tiết đăng ký

Analyze Date	2026-08-04 08:01:29
Symbol	EXEL
Name	EXELIXIS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	251.36 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	13,329.36 / 9,645.64

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502

Phone: 650 837 7000

Website: https://www.exelixis.com

Employees: 1,077

Sector: Healthcare >> Biotechnology

Description: Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.